11/19/2019
Abrilada is the fifth Humira biosimilar approved in the U.S. and will join generics from Mylan, Samsung Bioepis and Sandoz when AbbVie's blockbuster has its patent expire in 2023.
11/19/2019
The Swiss drugmaker will pay $390 million upfront for the privately held biotechnology company specializing in the development of targeted medicines to treat fibrosis.
11/19/2019
Facing stiffening biosimilar and generics competition, Amgen said it has to cut 172 jobs later this year.
11/19/2019
The U.S. Supreme Court has turned down an appeal attempt by Martin Shkreli this week.
11/18/2019
England's National Health Service is running short of dozens of lifesaving medicines including treatments for cancer, heart conditions and epilepsy, according to an internal document circulated to doctors.
11/17/2019
Novartis announced it won U.S. FDA approval for its experimental sickle cell disease drug, Adakveo.
11/15/2019
Most popular Pharma Manufacturing stories from the past seven days.
11/15/2019
Japan's Shionogi announced the U.S. FDA has approved its new antibiotic, Fetroja, for the treatment of complicated urinary tract infections.
11/13/2019
Heparin, one of the world’s most critical heart medications, could soon run in short supply due to an outbreak of African swine fever that’s wiped out nearly a quarter of the world’s pigs.
